Investigators identified candidate protein markers from aptamer-based proteomic profiles of samples from women with or without late-onset preeclampsia.
The funds come from an equity investment by Chinese health firm iCarbonX announced at the beginning of the year as part of a partnership between the companies.
Though considered potential antibody alternatives, these reagents are more likely to succeed in new applications for which conventional tools are poorly suited.
A company researcher said the new structure could provide the chemical diversity needed to build a set of reagents targeting the full human proteome.
The bioinformatics startup has also invested in six other companies, committing $400 million to its data-sharing collaboration.
The company has identified markers of latent disease that it is now investigating to see if they could be useful for predicting progression to active infection.
The developer has presented clinical results that provide a base for completing development of a multi-protein test kit and conducting a clinical trial in advance of FDA submission.
The European Commission recently awarded the researchers €1.5 million to probe the mechanics of heart failure using proteomic, genomic, and epidemiological approaches.
The company this week published a study in JAMA describing the panel, which is intended for assessing the risk of adverse events in coronary heart disease patients.
The firm said it will use the funds to support development of new life science tools and clinical diagnostics based on its Somamer affinity agent technology.
A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.
Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.
Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.
In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.